Comprehensive Preclinical Evaluation of STEAP1×CD3 T-cell Engager Using GemPharmatech’s Integrated Platform

STEAP1 is a highly attractive prostate cancer-specific antigen with restricted normal tissue expression, making it an ideal target for T-cell engager (TCE) immunotherapy. GemPharmatech established an integrated preclinical platform that combines in vitro functional assays with in vivo efficacy studies in humanized mouse models to comprehensively evaluate STEAP1×CD3 bispecific antibodies. The platform enables simultaneous assessment of antigen-dependent T-cell activation, cytotoxicity, tumor infiltration, antitumor efficacy, and cytokine profiles. Using the clinical-stage STEAP1×CD3 TCE Xaluritamig (AMG 509) as a benchmark, the system demonstrated robust coordinated evaluation capabilities, supporting translational development of next-generation T-cell engagers.